DATA GRAPHICS | Data Byte
On the positive side of the ledger, BMS’s CAR T therapy Abecma headed for a line extension
By Gunjan Ohri, Data Content Analyst
January 27, 2024 12:11 AM UTC
Negative opinions and non-renewals headlined this month’s recommendations from EMA’s CHMP.
After re-examination. EMA’s CHMP has again concluded that the effectiveness of Duchenne muscular dystrophy therapy Translarna ataluren from PTC Therapeutics Inc. (NASDAQ:PTCT) cannot be confirmed from Phase III study 041, which was required to convert the drug’s conditional authorization, granted in 2014, to full approval. The agency noted that the mechanism of action could not be confirmed from additional studies showing a small effect on dystrophin protein production. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651278/ema-s-chmp-confirms-non-renewal-of-translarna-denies-new-medicines-nezglyal-and-syfovre